We hope you are finding value in our Pharma Stocks Today newsletters, the breaking news and the advertisers that we source for you. If at any time you want to stop reading these free goodies, simply unsubscribe. | | | Dear Reader, We have been sharing information all month long about our Featured Company Cardiol Therapeutics and we're excited to share something truly special. Cardiol Therapeutics' journey towards redefining heart disease treatment has reached a pivotal milestone, and we want you to hear the news straight from the source. A Groundbreaking Announcement from CEO David Elsley (tap here to watch the video) David Elsley, CEO of Cardiol Therapeutics, recently sat down with Steve Darling from Proactive Investors to discuss a monumental achievement: the FDA's Orphan Drug Designation (ODD) for their leading drug candidate, CardiolRx™, aimed at treating pericarditis, including the challenging recurrent pericarditis. This designation marks a significant validation of the drug's potential to significantly improve the lives of those suffering from this debilitating heart condition. Why This Matters Recurrent pericarditis is not just a disease; it's a life-altering challenge for those affected, severely impacting their quality of life and ability to perform daily activities. The FDA's ODD underscores the innovative potential of CardiolRx™ to change these patients' lives for the better. Inside the MAvERIC-Pilot Study The MAvERIC-Pilot is a Phase II open-label pilot study that explores the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. With its focus on both safety and objective improvement measures, this study is a critical step towards offering new hope to those affected by this rare disease. The Power of Orphan Drug Designation ODD by the FDA is granted to treatments developed for rare diseases affecting fewer than 200,000 people in the U.S. This designation brings several advantages, including the potential for seven-year market exclusivity, FDA fee exemptions, and tax credits for clinical trials. Crucially, it may also lead to accelerated regulatory review, placing CardiolRx™ on a fast track to making a real-world impact. Watch the Full Video Now To hear directly from CEO David Elsley about this exciting development and what it means for the future of Cardiol Therapeutics and its patients, click the link below: [Watch the Exclusive Interview with David Elsley] This milestone is not just a win for Cardiol Therapeutics; it's a promising development for anyone invested in the future of cardiovascular health and innovation. Thank you for joining us through this welcome series. We're excited to continue bringing you the latest in investment opportunities and breakthroughs in healthcare. Best, The Pharma Stocks Today Team P.S. Stay tuned for more exclusive content and updates in our newsletter, every Tuesday and Thursday. And take a moment to read this article on Cardiol | | | LEGAL DISCLAIMERS - THIS IS A PAID ADVERTISEMENT.
This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading this email, our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.
This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.
As a result of this communication we will be dropping you in a variety of places featuring Cardiol Therapeutics; including but not limited to, directly on the Press Release that is hosted on the profiled Company's site here; and the featured interview on FinTech.TV here.
COMPENSATION DISCLOSURE.
IRP Holdings, dba IRPub, has received Seventy-Five Thousand Dollars paid by a third party, Anchor IR LLC, for and on behalf of Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) for brand awareness, marketing distribution and investor education marketing for a period of 30 Days. IRPub has not received any shares nor owns any shares of Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL), however, Anchor IR has received a contract from the company containing an offer to purchase Stock Options at a strike price of $2.56 CAD. The total amount of options that may be exercised/purchased is up to 150,000 Shares. This Stock Option Agreement is NOT an award of shares to Anchor IR, it is an opportunity for Anchor IR to take a position in the company pursuant to the Agreement. Should Anchor IR decide to execute their Options, this information will be updated and disclosed immediately reflecting the amount of options executed and the date of execution.
DISCLOSURE OF HOLDINGS
PharmaStocksToday, IRP Holdings Corporation dba IRPub, DO NOT hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. We have been paid to produce this piece by the Company or companies mentioned above. However, Anchor IR, a partner company to IRP Holdings, has received a contract from the company containing an offer to purchase Stock Options at a strike price of $2.56 CAD. The total amount of options that may be exercised/purchased is up to 150,000 Shares. This Stock Option Agreement is NOT an award of shares to AnchorIR LLC, it is an opportunity for Anchor IR to take a position in the company pursuant to the Agreement. Should Anchor IR decide to execute their Options, this information will be updated and disclosed immediately reflecting the amount of options executed and the date of execution.
THIS IS A PAID ADVERTISEMENT.
This communication is a paid advertisement and is not a recommendation to buy or sell securities. IRPub, and its owners, managers, employees, and assigns (collectively "the Company") has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by a third party, Anchor IR LLC, for and on behalf of Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL), Seventy-Five Thousand Dollars US dollars for marketing services for a period of 45 days. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication.
Gains mentioned in this article, in our newsletter and on our website may be based on end-of-day or intraday data. We have been compensated by a third party, AnchorIR LLC, for and on behalf of Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) to conduct investor awareness advertising and marketing. Therefore, this communication should be viewed as a commercial advertisement only. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IRP & Anchor IR often employ independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, and approved by the company that is featured herein, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s).
This email and possible webpage(s), are owned, operated and edited by IRP Holdings Corporation. Any wording found on this email, or our website / media webpages or disclaimer referencing to "I" or "we" or "our" or "IRP" or "IRPub" refers to IRP Holdings Corporation. This website / media webpages is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpages are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpages may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we/they may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here: as mentioned above IRP Holdings does not own shares in the profiled company, However, Anchor IR, a partner company to IRP Holdings, has received a contract from the company containing an offer to purchase Stock Options at a strike price of $2.56 CAD. The total amount of options that may be exercised/purchased is up to 150,000 Shares. This Stock Option Agreement is NOT an award of shares to Anchor IR, it is an opportunity for Anchor IR to take a position in the company pursuant to the Agreement. Should Anchor IR decide to execute their Options, this information will be updated and disclosed immediately reflecting the amount of options executed and the date of execution.
Again, IRP Holdings Corporation and AnchorIR LLC's business models are to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IRP Holdings and Anchor IR LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
We have not thoroughly investigated the background of Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL). The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment
RISK OF INVESTING.
Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on Companies. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
INFORMATION
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. This communication is based on information generally available to the public and on an interview conducted with the company's CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views. You can email contact to support@irpub.com.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual's financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company's SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company's actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company's operations; the size and growth of the market for the company's products and services; the company's ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company's business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
TERMS OF USE AND DISCLAIMER
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
INTELLECTUAL PROPERTY
All trademarks used in this communication are the property of their respective trademark holders. Other than PharmaStocksToday.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than PharmaStocksToday.com.
AUTHORS PARTNER CONTENT
All of the content found on this page was authored by our 3rd party affiliate partner. PharmaStocksToday, IRP Holdings Corporation dba IRPub, and our affiliates are not responsible for the content or accuracy of this article.
DISCLOSURE OF HOLDINGS
PharmaStocksToday, IRP Holdings Corporation dba IRPub, DO NOT hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. We have been paid to produce this piece by the Company or companies mentioned above. However, Anchor IR, a partner company to IRP Holdings, has received a contract from the company containing an offer to purchase Stock Options at a strike price of $2.56 CAD. The total amount of options that may be exercised/purchased is up to 150,000 Shares. This Stock Option Agreement is NOT an award of shares to AnchorIR LLC, it is an opportunity for Anchor IR to take a position in the company pursuant to the Agreement. Should Anchor IR decide to execute their Options, this information will be updated and disclosed immediately reflecting the amount of options executed and the date of execution. | | | |
No comments:
Post a Comment